Reason for request
Extension of the indication
Clinical Benefit
Clinical Added Value
| moderate |
Given the efficacy of VOTUBIA (everolimus) in reducing renal angiomyolipoma volume associated with tuberous sclerosis complex in adult patients, VOTUBIA provides a substantial improvement in actual benefit (IAB III) in the treatment of patients not requiring immediate surgery (nephrectomy or embolisation). |
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
577VymhhADcQCC35
